Cardiol expands trial enrollment to 150 patients
Share
Cardiol Therapeutics (NASDAQ:CRDL) reached its original enrollment target for the Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and plans to expand enrollment to up to 150 patients.
